INSITE VISION
InSite Vision is committed to advancing new and superior ophthalmologic products for unmet eye care needs. The company's product portfolio utilizes InSite Vision's proven DuraSite(R) bioadhesive polymer core technology, an innovative platform that extends the duration of drug retention on the surface of the eye, thereby reducing frequency of treatment and improving the efficacy of topically delivered drugs. The DuraSite platform is currently leveraged in two commercial products for the treatment... of bacterial eye infections, AzaSite(R) (azithromycin ophthalmic solution) 1%, marketed in the U.S. by Inspire Pharmaceuticals, and Besivance(TM) (besifloxacin ophthalmic suspension) 0.6%, marketed by Bausch & Lomb and their partner Pfizer Inc. InSite Vision's clinical-stage ophthalmic product pipeline includes AzaSite Plus(TM) (ISV-502) and ISV-305 for the treatment of eye infections, ISV-303 for pain and swelling associated with ocular surgery, and ISV-101 for the treatment of dry eye disease.
INSITE VISION
Industry:
Biotechnology Pharmaceutical Therapeutics
Founded:
1986-01-01
Address:
Alameda, California, United States
Country:
United States
Website Url:
http://www.insitevision.com
Total Employee:
11+
Status:
Active
Contact:
(151) 074-7122
Total Funding:
24.57 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SSL By Default Google Font API LetsEncrypt WordPress Sitelinks Search Box IPv6 Yoast WordPress SEO Plugin Cloudflare
Current Advisors List
Board_member
2008-01-01
Current Employees Featured
Kamran Hosseini CMO @ InSite Vision
CMO
Timothy Ruane CEO @ InSite Vision
CEO
2010-12-01
Official Site Inspections
http://www.insitevision.com Semrush global rank: 7.74 M Semrush visits lastest month: 437
- Host name: 172.67.217.77
- IP address: 172.67.217.77
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "InSite Vision"
InSite Vision - Crunchbase Company Profile & Funding
InSite Vision is committed to advancing new and superior ophthalmologic products for unmet eye care needs. The company's product portfolio utilizes InSite Vision's proven DuraSite(R) bioadhesive polymer core technology, an …See details»
Insite Vision Company Profile 2024: Valuation, …
Insite Vision General Information Description. Developer of ophthalmic products focused on ocular infection, glaucoma and retinal disease. The company develops and commercializes ophthalmic pharmaceutical products based on …See details»
InSite Vision, Inc. Overview | SignalHire Company Profile
Phone Number: 510-865-8800: InSite Vision, Inc. industries Pharma, Pharmaceuticals: InSite Vision, Inc. Employees SizeSee details»
About Insite Vision Inc (INSV) - Investing.com
This page offers an in-depth profile of Insite Vision Inc, including a general overview of the company's business and key management.See details»
InSite Vision Inc - Company Profile and News - Bloomberg Markets
Company profile page for InSite Vision Inc including stock price, company news, executives, board members, and contact informationSee details»
Sun Pharma to acquire InSite Vision
Sun Pharmaceutical Industries Ltd. SUN HOUSE, CTS No. 201 B/1, Western Express Highway, Goregaon (E), Mumbai 400063, India Tel.: (91-22) 4324 4324 Fax.: (91-22) 4324 4343See details»
Insite Vision, Inc. | Golden
Insite Vision, Inc. is an Alameda, California-based company in the pharmaceuticals industry founded in 1986.See details»
InSite Vision, Inc | VentureRadar
Similar Companies: Nanovector USA Privately Held NanoVector is a pre-clinical stage therapeutic drug company developing the world’s first commercially viable biologic nanoparticle-based …See details»
InSite Vision, Inc - VentureRadar
Website: http://www.insitevision.com. InSite Vision is committed to advancing new and superior ophthalmologic products for unmet eye care needs.See details»
InSite Vision, Inc. | Insights
Dec 5, 2016 Already A Biomedtracker Subscriber? You have access to the full company record through your subscription.See details»
InSite Vision (INSV) Stock Price, News & Analysis - MarketBeat
2 days ago InSite Vision Incorporated is an ophthalmic product development company that offers ophthalmic pharmaceutical products. The Company's portfolio of products is based on its …See details»
Insite Vision Inc. : InSite Vision Introduces DuraSite 2® Ophthalmic ...
Sep 5, 2012 For further information on InSite Vision, please visit www.insitevision.com. Forward-looking Statements. This news release contains certain statements of a forward looking nature …See details»
InSite Vision Selects Quintiles as Contract Research Organization …
Sep 28, 2011 ALAMEDA, Calif.--(BUSINESS WIRE)--InSite Vision Incorporated (OTCBB:INSV) today announced the selection of Quintiles as the contract research organization to manage …See details»
InSite Vision Inc. | Alameda CA - Facebook
InSite Vision Inc., Alameda, California. 181 likes · 4 were here. InSite Vision develops ophthalmic products designed to treat a growing range of common...See details»
InSite Vision Announces Positive Phase 3 Results for BromSite
Mar 19, 2013 InSite Vision is also advancing three novel ophthalmic therapeutics through Phase 3 clinical studies: AzaSite Plus™ and DexaSite™ for the treatment of eye infections, and …See details»
Timothy Ruane - InSite Vision, Inc. | LinkedIn
Experience: InSite Vision, Inc. · Education: University of Washington · Location: Alameda · 500+ connections on LinkedIn. View Timothy Ruane’s profile on LinkedIn, a professional community …See details»
InSite Vision Introduces DuraSite 2 - Drug Development and Delivery
InSite Vision is advancing a portfolio of novel preclinical to clinical-stage ophthalmic products based on the DuraSite platform and anticipates advancing future ophthalmic product …See details»
InSite Vision, Inc. (InSite Vision, Inc.) - 药物管线_专利_临床试验_投 …
了解InSite Vision, Inc. (InSite Vision, Inc.)公司的药物管线，治疗领域，技术平台，以及它的6篇新闻和6篇文献，药物:ISV-616，ISV-208，巴马司他，Diclofenac，ISV-215。See details»
InSite Vision (ISV) Announces FDA Approval Of New
Jun 4, 2009 InSite Vision Incorporated (OTCBB:INSV - News) today announced that Bausch & Lomb has received approval of Besivance™ (besifloxacin ophthalmic suspension) 0.6% for the …See details»
InSite Vision Announces Top-Line Results From the DOUBle
Jul 24, 2013 InSite Vision is also advancing three novel ophthalmic therapeutics through Phase 3 clinical studies: AzaSite Plus™ and DexaSite™ for the treatment of eye infections, and …See details»